[1] |
中华医学会肿瘤学分会,中华医学会杂志社. 中华医学会胃癌临床诊疗指南(2021版)[J]. 中华医学杂志, 2022, 102(16): 1169-1189.
|
[2] |
Xia C, Dong X, Li H, et al. Cancer statistics in China and United States, 2022: profiles, trends, and determinants[J]. Chin Med J (Engl), 2022, 135(5): 584-590.
|
[3] |
Ajani JA, D’Amico TA, Bentrem DJ, et al. Gastric cancer, Version 2.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw, 2022, 20(2): 167-192.
|
[4] |
陈俊良,王风华. 2021版CSC0胃癌诊疗指南转移性胃癌更新解读[J]. 中国肿瘤临床, 2022, 49(7): 325-330.
|
[5] |
Muro K, Van Cutsem E, Narita Y, et al. Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: A JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS[J]. Ann Oncol, 2019, 30(1): 19-33.
|
[6] |
Lee KW, Chung IJ, Ryu MH, et al. Multicenter phase Ⅲ trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial) [J]. Gastric Cancer, 2021, 24(1): 156-167.
|
[7] |
蒋进发,周翰宗,季节. 替吉奥联合奥沙利铂或顺铂治疗进展期胃癌的临床效果[J]. 中国医药指南, 2017, 15(11): 139-140.
|
[8] |
Hamada C, Yamada Y, Azuma M, et al. Meta-analysis supporting noninferiority of oxaliplatin plus S-1 to cisplatin plus S-1 in first-line treatment of advanced gastric cancer (G-SOX study): indirect comparison with S-1 alone[J]. Int J Clin Oncol, 2016, 21(4): 668-675.
|
[9] |
Kang YK, Chin K, Chung HC, et al. S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin as first-line therapy in patients with advanced gastric cancer (SOLAR): A randomised, open-label, phase 3 trial[J]. Lancet Oncol, 2020, 21(8): 1045-1056.
|
[10] |
Hironaka S, Sugimoto N, Yamaguchi K, et al. S-1 plus leucovorin versus S-1 plus leucovorin and oxaliplatin versus S-1 plus cisplatin in patients with advanced gastric cancer: A randomised, multicentre, open-label, phase 2 trial[J]. Lancet Oncol, 2016, 17(1): 99-108.
|
[11] |
蔡小彪,邓月兰. 替吉奥联合奥沙利铂治疗转移性胃癌的疗效观察[J]. 黑龙江医药, 2022, 35(1): 95-97.
|
[12] |
赵泽. SOX方案与SP方案治疗晚期胃癌患者的效果比较 [J]. 中国民康医学, 2021, 33(15): 141-142.
|
[13] |
肖月,王瑛,张旭阳, 等. 替吉奥联合奥沙利铂对比替吉奥联合顺铂治疗老年晚期胃癌的临床分析[J/CD]. 临床医药文献电子杂志, 2019, 6(43): 74.
|
[14] |
蔡延庆. 探究替吉奥联合奥沙利铂治疗老年晚期胃癌的临床效果及安全性[J]. 现代诊断与治疗, 2018, 29(17): 2706-2708.
|
[15] |
杨庆辉,路平. 替吉奥与不同药物联合治疗老年晚期胃癌的临床效果研究[J]. 海峡药学, 2017, 29(5): 145-146.
|
[16] |
王村. 比较替吉奥联合奥沙利铂、替吉奥联合顺铂方案一线治疗老年晚期胃癌的实际作用 [J/CD]. 临床医药文献电子杂志, 2017, 4(2): 20144-20145.
|
[17] |
田彩,杨继. SOX化疗方案治疗对老年晚期胃癌患者免疫功能的影响[J]. 医学新知杂志, 2017, 27(5): 474-476.
|
[18] |
宋仲洁. 替吉奥联合奥沙利铂化疗方案治疗老年晚期胃癌的临床研究[J]. 癌症进展, 2016, 14(2): 162-164.
|
[19] |
薛向生. 替吉奥联合奥沙利铂治疗老年晚期胃癌的疗效观察[J]. 中国实用医刊, 2015, 42(8): 30-31.
|
[20] |
Yamada Y, Higuchi K, Nishikawa K, et al. Phase Ⅲ study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer[J]. Ann Oncol, 2015, 26(1): 141-148.
|
[21] |
Yang J, Zhou Y, Min K, et al. S-1-based vs non-S-1-based chemotherapy in advanced gastric cancer: A meta-analysis [J]. World J Gastroenterol, 2014, 20(33): 11886-11893.
|
[22] |
杨炜,张喆. 替吉奥联合奥沙利铂对比替吉奥联合顺铂治疗晚期胃癌的系统评价[J]. 检验医学与临床, 2020, 17(15): 2150-2152, 2156.
|
[23] |
宋莹,霍庚崴. 替吉奥联合顺铂对比替吉奥联合奥沙利铂治疗晚期胃癌疗效和安全性的系统评价[J]. 健康之友, 2020, (1): 3.
|
[24] |
Bando H, Yamada Y, Tanabe S, et al. Efficacy and safety of S-1 and oxaliplatin combination therapy in elderly patients with advanced gastric cancer[J]. Gastric Cancer, 2016, 19(3): 919-926.
|
[25] |
Yagi S, Yamada K, Terayama M, et al. Current status of doublet combinations of platinum and fluoropyrimidines using oxaliplatin for advanced gastric cancer[J]. Glob Health Med, 2021, 3(1): 31-36.
|
[26] |
Kang L, Tian Y, Xu S, et al. Oxaliplatin-induced peripheral neuropathy: clinical features, mechanisms, prevention and treatment[J]. J Neurol, 2021, 268(9): 3269-3282.
|